Market closedNon-fractionalADR
GENFIT/GNFT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About GENFIT
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Ticker
GNFT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Loos, France
Employees
159
Website
www.genfit.fr
GENFIT Metrics
BasicAdvanced
$255M
Market cap
-
P/E ratio
-$0.63
EPS
1.18
Beta
-
Dividend rate
Price and volume
Market cap
$255M
Beta
1.18
52-week high
$6.05
52-week low
$2.89
Average daily volume
0.24
Financial strength
Current ratio
2.94
Quick ratio
2.939
Long term debt to equity
91.615
Total debt to equity
103.269
Interest coverage (TTM)
-7.78%
Management effectiveness
Return on assets (TTM)
-14.84%
Return on equity (TTM)
-35.57%
Return on investment (TTM)
-18.55%
Valuation
Price to revenue (TTM)
6.16
Price to book
3.504
Price to tangible book (TTM)
12.254
Growth
Revenue change (TTM)
43.70%
Earnings per share change (TTM)
-21.75%
3-year revenue growth (CAGR)
70.09%
GENFIT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€23M
49.02%
Net income
-€8M
-61.54%
Profit margin
-35.08%
-74.19%
GENFIT News
AllArticlesVideos
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
GlobeNewsWire·12 hours ago
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GlobeNewsWire·2 weeks ago
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GENFIT stock?
GENFIT (GNFT) has a market cap of $255M as of July 27, 2024.
What is the P/E ratio for GENFIT stock?
The price to earnings (P/E) ratio for GENFIT (GNFT) stock is 0 as of July 27, 2024.
Does GENFIT stock pay dividends?
No, GENFIT (GNFT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next GENFIT dividend payment date?
GENFIT (GNFT) stock does not pay dividends to its shareholders.
What is the beta indicator for GENFIT?
GENFIT (GNFT) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell GENFIT stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.